Maria Pineda | BiotechTV

top of page

BIO-Europe 2026: Envisagenics is harnessing RNA splicing as its therapeutic approach - which may open up biology to novel targets

Co-Founder & CEO Maria Pineda describes the idea behind RNA splicing, which the company is using initially against (currently unnamed) CNS and oncology targets. It also recently announced a multi-target collaboration with Boehringer Ingelheim for oncology. Coverage brought to you by

Company News

56 minutes ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more

bottom of page

BIO-Europe 2026: Envisagenics is harnessing RNA splicing as its therapeutic approach - which may open up biology to novel targets

Follow BiotechTV

Sponsors

Sponsor Spotlight